Advertisement

More articles from Erratum

You have access
Correction to “A Refined Cytochrome P540 IC₅₀ Shift Assay for Reliably Identifying CYP3A Time-Dependent Inhibitors”
Drug Metabolism and Disposition September 2011, 39 (9) 1777; DOI: https://doi.org/10.1124/dmd.39.9.1777
You have access
Correction to “Disposition and Metabolism of [¹⁴C]SB-649868, an Orexin 1 and 2 Receptor Antagonist, in Humans”
Drug Metabolism and Disposition June 2011, 39 (6) 1111; DOI: https://doi.org/10.1124/dmd.39.6.1111
You have access
Correction to Table of Contents, volume 39, number 3, March 2011
Drug Metabolism and Disposition May 2011, 39 (5) 938; DOI: https://doi.org/10.1124/dmd.39.5.938
You have access
CORRECTION TO “Influence of Cremophor EL and Genetic Polymorphisms on the Pharmacokinetics of Paclitaxel and Its Metabolites Using a Mechanism-Based Model”
Drug Metabolism and Disposition March 2011, 39 (3) 563; DOI: https://doi.org/10.1124/dmd.39.3.563
You have access
CORRECTION TO “IDENTIFICATION OF CLINICALLY UTILIZED DRUGS THAT ACTIVATE PREGNANE X RECEPTORS”
Drug Metabolism and Disposition February 2011, 39 (2) 351; DOI: https://doi.org/10.1124/dmd.39.2.351
You have access
Correction to “Predictability of Idiosyncratic Drug Toxicity Risk for Carboxylic Acid-Containing Drugs Based on the Chemical Stability of Acyl Glucuronide”
Drug Metabolism and Disposition December 2010, 38 (12) 2347; DOI: https://doi.org/10.1124/dmd.38.12.2347
You have access
Correction to “Quantifying the Metabolic Activation of Nevirapine in Patients by Integrated Applications of NMR and Mass Spectrometries”
Drug Metabolism and Disposition July 2010, 38 (7) 1259; DOI: https://doi.org/10.1124/dmd.38.7.1259
You have access
Correction to “5′-Aminocarbonyl Phosphonates as New Zidovudine Depot Forms: Antiviral Properties, Intracellular Transformations, and Pharmacokinetic Parameters”
Drug Metabolism and Disposition July 2010, 38 (7) 1258; DOI: https://doi.org/10.1124/dmd.38.7.1258
You have access
Correction to “In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies”
Drug Metabolism and Disposition May 2010, 38 (5) 887; DOI: https://doi.org/10.1124/dmd.109.000019
You have access
CORRECTION TO “CHARACTERIZATION OF DASATINIB AND ITS STRUCTURAL ANALOGS AS CYP3A4 MECHANISM-BASED INACTIVATORS AND THE PROPOSED BIOACTIVATION PATHWAYS”
Drug Metabolism and Disposition October 2009, 37 (10) 2118; DOI: https://doi.org/10.1124/dmd.37.10.2118

Pages